

JOURNAL OF CLINICAL ONCOLOGY

Official Journal of the American Society of Clinical Oncology

Vol 27, No 20

C O N T E N T S

July 10, 2009

Editorials

Duration of Chemotherapy for Metastatic Non–Small-Cell Lung Cancer: More May Be Better After All

Joan H. Schiller and Suresh S. Ramalingam (see editorial on page 3268 and article on page 3277) 3265

Re-Evaluating Duration of Therapy in Advanced Non–Small-Cell Lung Cancer: Is It Really Duration or Is It More About Timing and Exposure?

Mark A. Socinski (see editorial on page 3265 and article on page 3277) 3268

Metformin in Breast Cancer: Time for Action

Pamela J. Goodwin, Jennifer A. Ligibel, and Vuk Stambolic (see article on page 3297) 3271

Targeting Renal Cell Carcinoma

Robert J. Motzer and Ana M. Molina (see article on page 3312) 3274

Original Reports

THORACIC ONCOLOGY

① Duration of Chemotherapy for Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials

Yu Yang Soon, Martin R. Stockler, Lisa M. Askie, and Michael J. Boyer (see editorials on pages 3265 and 3268) 3277

① Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Thomas A. Hensing, Alfred Rademaker, Eric M. Hart, Matthew G. Blum, Daniel T. Milton, and Philip D. Bonomi 3284

① Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy

Pia Baumann, Jan Nyman, Morten Hoyer, Berit Wennberg, Giovanna Gagliardi, Ingmar Lax, Ninni Drugge, Lars Ekberg, Signe Friesland, Karl-Axel Johansson, Jo-Åsmund Lund, Elisabeth Morhed, Kristina Nilsson, Nina Levin, Merete Paludan, Christer Sederholm, Anders Traberg, Lena Wittgren, and Rolf Lewensohn 3290

(continued on following page)

Journal of Clinical Oncology (ISSN 0732-183X) is published 36 times a year, three times monthly, by American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Periodicals postage is paid at Alexandria, VA, and at additional mailing offices. Publication Mail Agreement Number 863289.

Editorial correspondence should be addressed to Daniel G. Haller, MD, *Journal of Clinical Oncology*, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Telephone: (703) 797-1900; Fax: (703) 684-8720. E-mail: jco@asco.org. Internet: www.jco.org.

POSTMASTER: ASCO members send change of address to American Society of Clinical Oncology, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Nonmembers send change of address to *Journal of Clinical Oncology* Customer Service, 2318 Mill Road, Suite 800, Alexandria, VA 22314.

2009 annual subscription rates, effective September 1, 2008: United States and possessions: individual, \$556; single issue, \$40. International: individual, \$772; single issue, \$50. Institutions: Tier 1: \$786 US, \$1,086 Int'l; Tier 2: \$915 US, \$1,214 Int'l; Tier 3: \$1,321 US, \$1,610 Int'l; Tier 4: \$1,455 US, \$1,744 Int'l; Tier 5: contact JCO for a quote. See <http://www.jco.org/subscriptions/tieredpricing.shtml> for descriptions of each tier. Student and resident: United States and possessions: \$278; all other countries, \$386. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Subscriptions are accepted on a 12-month basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability. JCO Legacy Archive (electronic back issues from January 1983 through December 1998) is also available; please inquire.

BREAST CANCER

① **Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer**

Sao Jiralerspong, Shana L. Palla, Sharon H. Giordano, Funda Meric-Bernstam, Cornelia Liedtke, Chad M. Barnett, Limin Hsu, Mien-Chie Hung, Gabriel N. Hortobagyi, and Ana M. Gonzalez-Angulo (see editorial on page 3271) 3297

Circulating Tumor Cells and [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Outcome Prediction in Metastatic Breast Cancer

Ugo De Giorgi, Vicente Valero, Eric Rohren, Shaheenah Dawood, Naoto T. Ueno, M. Craig Miller, Gerald V. Doyle, Summer Jackson, Eleni Andreopoulou, Beverly C. Handy, James M. Reuben, Herbert A. Fritsche, Homer A. Macapinlac, Gabriel N. Hortobagyi, and Massimo Cristofanilli 3303

GENITOURINARY CANCER

① **Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial**

Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Negrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, Gloria Hofileña, Minghua Shan, Carol Pena, Chetan Lathia, and Ronald M. Bukowski (see editorial on page 3274) 3312

① **Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer**

Shi-Ming Tu, Paul Mathew, Franklin C. Wong, Donnah Jones, Marcella M. Johnson, and Christopher J. Logothetis 3319

Two-Center Evaluation of Dynamic Sentinel Node Biopsy for Squamous Cell Carcinoma of the Penis

Joost A.P. Leijte, Ben Hughes, Niels M. Graafland, Bin K. Kroon, Renato A. Valdés Olmos, Omgo E. Nieweg, Cathy Corbishley, Sue Heenan, Nick Watkin, and Simon Horenblas 3325

MELANOMA

① **Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma**

Trine O. Jensen, Henrik Schmidt, Holger Jon Møller, Morten Høyer, Maciej Bogdan Maniecki, Pia Sjoegren, Ib Jarle Christensen, and Torben Steiniche 3330

HEALTH SERVICES AND OUTCOMES

① **Primary Care Physicians' Views of Routine Follow-Up Care of Cancer Survivors**

M. Elisabeth Del Giudice, Eva Grunfeld, Bart J. Harvey, Eugenia Piliotis, and Sunil Verma 3338

LYMPHOMA AND MYELOMA

① **Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results**

Franck Morschhauser, John P. Leonard, Luis Fayad, Bertrand Coiffier, Marie-Odile Petillon, Morton Coleman, Stephen J. Schuster, Martin J.S. Dyer, Heather Horne, Nick Teoh, William A. Wegener, and David M. Goldenberg 3346

① **Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center**

Jason S. Knight, Alexander Tsodikov, Diane M. Cibrik, Charles W. Ross, Mark S. Kaminski, and Douglas W. Blayney 3354

PEDIATRIC ONCOLOGY

① **Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group**

Birgit Burkhardt, Alfred Reiter, Eva Landmann, Peter Lang, Lisa Lassay, Roswitha Dickerhoff, Max Lakomek, Günter Henze, and Arend von Stackelberg 3363

TRANSLATIONAL ONCOLOGY

Single Nucleotide Polymorphism at rs1982073:T869C of the *TGFβ1* Gene Is Associated With the Risk of Radiation Pneumonitis in Patients With Non-Small-Cell Lung Cancer Treated With Definitive Radiotherapy

Xianglin Yuan, Zhongxing Liao, Zhensheng Liu, Li-E Wang, Susan L. Tucker, Li Mao, Xin Shelley Wang, Mary Martel, Ritsuko Komaki, James D. Cox, Luka Milas, and Qingyi Wei 3370

GASTROINTESTINAL CANCER

① **Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment**

George A. Poultsides, Elliot L. Servais, Leonard B. Saltz, Sujata Patil, Nancy E. Kemeny, Jose G. Guillem, Martin Weiser, Larissa K.F. Temple, W. Douglas Wong, and Phillip B. Paty 3379

① **Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer**

Carmen J. Allegra, Greg Yothers, Michael J. O'Connell, Saima Sharif, Linda H. Colangelo, Samia H. Lopa, Nicholas J. Petrelli, Richard M. Goldberg, James N. Atkins, Thomas E. Seay, Louis Fehrenbacher, Seamus O'Reilly, Luis Chu, Catherine A. Azar, and Norman Wolmark 3385

SARCOMAS

① **Comparing Adult and Pediatric Rhabdomyosarcoma in the Surveillance, Epidemiology and End Results Program, 1973 to 2005: An Analysis of 2,600 Patients**

Iyad Sultan, Ibrahim Qaddoumi, Sameer Yaser, Carlos Rodriguez-Galindo, and Andrea Ferrari 3391

Review Article

Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation

Mauricette Michallet and James I. Ito 3398

e. Diagnosis in Oncology

Gastrosplenic Fistula From Hodgkin's Lymphoma

Carolyn D. Seib, Flavio G. Rocha, Dick G. Hwang, and Brent T. Shoji e15

e. Correspondence

Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival

David J. Gallagher and Nancy E. Kemeny e18

Reply to D.J. Gallagher et al

Jean-Nicolas Vauthey, Daria Zorzi, Scott Kopetz, Eddie K. Abdalla, Yoji Kishi, and Dan G. Blazer III e20

Three Considerations Before Advising 5- α -Reductase Inhibitors for Chemoprevention

Patrick C. Walsh e22

Reply to P.C. Walsh

Barnett S. Kramer, Karen L. Hagerty, Mark R. Somerfield, and Paul Schellhammer e23

Errata

Sandler AB, Schiller JH, Gray R, et al: J Clin Oncol 27:1405-1412, 2009 3410

Stewart JSW, Cohen EEW, Licitra L, et al: J Clin Oncol 27:1864-1871, 2009 3410

Sargent DS, Köhne CH, Sanoff HK, et al: J Clin Oncol 27:1948-1955, 2009 3410

Also in This Issue

[Information for Subscribers](#)

[Information for Contributors](#)

[Manuscript Submission Checklist](#)

[Current Abstracts](#)

[Forthcoming Reports](#)



Online supplementary information available at www.jco.org



Diagnosis in Oncology and Correspondence available online at www.jco.org